- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Nerve Agent.
Displaying page 1 of 2.
EudraCT Number: 2005-006172-35 | Sponsor Protocol Number: 2005/EMER/18 | Start Date*: 2006-07-17 |
Sponsor Name:North Hampshire Hospital NHS Trust | ||
Full Title: A Randomised, Prospective, Double Blinded, Placebo Controlled Trial to Determine the Efficacy of Continuous Infusion Ankle Block Compared to Standard Single Bolus Block in the Management of Postope... | ||
Medical condition: Any Orthopaedic condition which would require ankle or hind foot surgery under Mr. James Calder at North Hampshire Hospital, Basingstoke. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011828-64 | Sponsor Protocol Number: FRS-AN2009-03-26 | Start Date*: 2009-08-03 |
Sponsor Name:Anesthesiological dep., Hospital of Frederikssund | ||
Full Title: Spinalanæstesi til knæartroskopi: Kan tilsætning af Lidokain til Bupivacain forkorte blokadens varighed? | ||
Medical condition: Duration of nerve blockade after spinal anesthesia with either bupivacaine or a mixture of bupivacaine/lidocaine. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002651-28 | Sponsor Protocol Number: IRST185.05 | Start Date*: 2018-02-22 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: Multi-cohort investigational study to evaluate the impact of pelvic mp-3TMRI and whole-body 68Ga-PSMA PET/CT for diagnosis of clinically-significant prostate cancer and pre-surgical staging. | |||||||||||||
Medical condition: prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006617-32 | Sponsor Protocol Number: 06/Q0605/1 | Start Date*: 2007-05-02 |
Sponsor Name:Kings College Hospital Trust R&D | ||
Full Title: A prospective randomised double blind parallel trial comparing Articaine versus Lignocaine for mandibular dentistry | ||
Medical condition: necessary dental surgery | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-005340-39 | Sponsor Protocol Number: S64807 | Start Date*: 2021-02-01 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Duodenal neuro-immune interactions and effects of proton pump inhibitors in functional dyspepsia | ||
Medical condition: Functional Dyspepsia (FD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004984-35 | Sponsor Protocol Number: EZH-501 | Start Date*: 2016-08-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Subjects will receive tazemetostat as dictated in their antecedent study. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) PL (Ongoing) BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001756-35 | Sponsor Protocol Number: 16/0163 | Start Date*: 2019-06-21 | |||||||||||
Sponsor Name:University of California, San Francisco | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Opti... | |||||||||||||
Medical condition: acute optic neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001568-35 | Sponsor Protocol Number: RGHT000559 | Start Date*: 2008-06-24 |
Sponsor Name:BELFAST HEALTH & SOCIAL CARE TRUST | ||
Full Title: Comparison of fascia iliac compartment block with conventional sedation to facilitate the positioning of patients with fractured neck of femur for spinal anaesthesia and the effect of nerve blockad... | ||
Medical condition: Investigation of the use a Fascia Iliaca nerve blockade for both positioning for spinal anaesthesia and postoperative analgesia in patients undergoing operative repair of fractured neck of femur. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004833-40 | Sponsor Protocol Number: EFC10518 | Start Date*: 2008-05-14 | |||||||||||
Sponsor Name:sanofi-aventis recherche & developpement | |||||||||||||
Full Title: A randomized, double blind, placebo controlled study evaluating the glycemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monoth... | |||||||||||||
Medical condition: Type 2 Diabetes patients insufficiently controlled with metformin monotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003357-85 | Sponsor Protocol Number: FRI200701 | Start Date*: 2007-10-10 | |||||||||||
Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | |||||||||||||
Full Title: Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study) | |||||||||||||
Medical condition: Friedreich ataxia (FRDA) is a rare autosomal recessive neurodegenerative disorder caused a mutation in the FXN gene, which encodes a protein named frataxin. As a result of the mutation, frataxin is... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015795-10 | Sponsor Protocol Number: SMA-09-19-SVN | Start Date*: 2009-11-12 |
Sponsor Name:Alcon d.o.o. | ||
Full Title: Assessing the safety and efficacy of switching to Azarga (Brinzolamide/Timolol Fixed Combination), as replacement therapy in patients with uncontrolled intraocular pressure | ||
Medical condition: uncontrolled intraocular pressure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002785-20 | Sponsor Protocol Number: EVIDIMS | Start Date*: 2011-09-19 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis | ||
Medical condition: Multiple Sclerosis and Clinical isolated Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-002419-87 | Sponsor Protocol Number: 008722 | Start Date*: 2014-03-18 | |||||||||||
Sponsor Name:Queen Mary University London | |||||||||||||
Full Title: Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003714-68 | Sponsor Protocol Number: 1744/2017 | Start Date*: 2017-11-15 | ||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||
Full Title: Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A prospective randomized clinical trial | ||||||||||||||||||
Medical condition: Evaluation of the effect of 80% versus 30% supplemental oxygen administration during major abdominal surgery on postoperative brain natriuretic peptide concentration. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004519-29 | Sponsor Protocol Number: APHP180351 | Start Date*: 2021-03-18 | ||||||||||||||||
Sponsor Name:Assistance Publique - Hôpitaux de Paris / DRCI | ||||||||||||||||||
Full Title: Multicenter randomized double-blind study comparing the efficacy and safety of belimumab in the treatment of non-infectious active cryoglobulinemia vasculitis compared to placebo TRIBECA STUDY (Tr... | ||||||||||||||||||
Medical condition: Adult patients with non-infectious active cryoglobulinemia vasculitis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002867-40 | Sponsor Protocol Number: 1 | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:Department of Anaesthesia | |||||||||||||
Full Title: Comparsion of continuous paravertebral blockade and continuous wound catheter infiltration for analgesia following mastectomy. | |||||||||||||
Medical condition: This study will involve the administration of levobupivicaine 0.125% and 0.25%, a local anaesthetic agent licensed for this purpose into the paravertebral space and into the surgical wound, to prov... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004998-17 | Sponsor Protocol Number: 0none | Start Date*: 2008-10-17 | |||||||||||
Sponsor Name:Department of Anaesethesia | |||||||||||||
Full Title: Comparison of continuous paravertebral blockade (PVB) and continuous thoracic epidural analgesia (TEA) for analgesia following open renal surgery | |||||||||||||
Medical condition: This study will involve the administration of levobupivacaine 0.25% and 0.125%, a local anaesthetic agent licensed for this purpose, into the epidural and paravertebral space, to provide postoperat... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003137-40 | Sponsor Protocol Number: F02207GE302 | Start Date*: 2015-09-28 |
Sponsor Name:Pierre Fabre Medicament | ||
Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome. | ||
Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001042-18 | Sponsor Protocol Number: J1O-MC-JZHD | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma | |||||||||||||
Medical condition: Relapsed/Refractory Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001553-14 | Sponsor Protocol Number: BGB-290-103 | Start Date*: 2018-06-29 |
Sponsor Name:BeiGene USA, Inc. | ||
Full Title: A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors | ||
Medical condition: Locally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastri... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.